Overall rank by patents
#1,874
of 49,997 tracked assignees
USPTO PatentsView assignee record - 214 granted patents across 37 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Glaxosmithkline ranks #1,874 of 49,997 tracked US assignees by granted-patent volume, with 214 patents across 37 technology areas.
USPTO PatentsView assignee plate
Corpus R1874 · Foreign Corporation #1,874 · 214 grants
GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL
Nearest grant-volume peer: AWI Licensing LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Construction… · near
53 score
GlaxoSmithKline… · this assignee
53 score
Paper Converting… · near
53 score
SAE Magnetics (H K ) · near
53 score
The Schepens Eye… · near
53 score
3D Lighting… · lowest
7 score
What this shows Glaxosmithkline's Innovation Score is 52.7/100 (top 10% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
GlaxoSmithKline Intellectual Property Development Limited is a focused PatentsView assignee: 37 CPC subclasses with 84.1% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (37 grants) versus a trough of 5 in 2016. By volume, Glaxosmithkline sits between Zoetis Services LLC and Minebea Co., Ltd..
From 2019–2021 to 2022–2024, GlaxoSmithKline Intellectual Property Development Limited moved from 97 to 45 grants (0.46x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,773. See the growth leaderboard.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Zoetis Services LLC
215 patents
AWI Licensing LLC
214 patents
Darfon Electronics Corp.
214 patents
F5 Networks, Inc.
214 patents
Grundfos Holding A/S
214 patents
Johnson Electric International AG
214 patents
MKS Instruments, Inc.
214 patents
Minebea Co., Ltd.
214 patents
GlaxoSmithKline Intellectual Property Development Limited
214 patents
What this shows GlaxoSmithKline holds 214 patents at rank #1,874, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #1,874 in granted patent volume.
Other assignees with the most granted patents in GlaxoSmithKline's primary technology class.
Two PlainPatent-derived peer sets for GlaxoSmithKline, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (53 here).
Nearest assignees by average claims per patent (15.9 here).
Glaxosmithkline's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
53 Top 10% higher than 90% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 7 | 3.3% |
| 2016 | 5 | 2.3% |
| 2017 | 21 | 9.8% |
| 2018 | 28 | 13.1% |
| 2019 | 37 | 17.3% |
| 2020 | 31 | 14.5% |
| 2021 | 29 | 13.6% |
| 2022 | 20 | 9.3% |
| 2023 | 14 | 6.5% |
| 2024 | 11 | 5.1% |
| 2025partial year | 11 | 5.1% |
Top 15 of 37 technology areas
Overall rank by patents
#1,874
of 49,997 tracked assignees
52.7 out of 100
What to do with this data
GlaxoSmithKline Intellectual Property Development Limited's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.